Fourth Quarter and Year End 2001 Conference Call, February 20, 2002 Dr. Metin Colpan, Managing Director and CEO Peer M. Schatz, Managing Director and

Transcription

1 Fourth Quarter and Year End 2001 Conference Call, February 20, 2002 Dr. Metin Colpan, Managing Director and CEO Peer M. Schatz, Managing Director and CFO

2 Forward Looking Statements Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN s products to integrated solutions and producing such products, the ability of each of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC). 2

3 Welcome to QIAGEN s Fourth Quarter and Year End 2001 Conference Call February 20, 2002 Conference Call Outline: - 20 min Presentation - 40 min Q&A session Due to time restrictions we would like to ask for only two questions per caller. 3

4 QIAGEN 2001 Revenues: 2001: $ million CAGR: 37% Net income: 2001: $ 36.5* million CAGR: 47%* EPS: 2001: $ 0.25* CAGR: 44%* Product range: Approx. 320 consumable products Instrumentation Increased range of in-licensed technologies IP: 238 issued patents, 235 pending patents Over 400 patents under license Customers: 400,000 scientists worldwide 4 (* excluding one-time charges related to the acquisition of Sawady Group of companies without considering any other impacts related to these acquisitions)

5 QIAGEN Core Competencies link into new LifeScience Areas Genomics Polyscience Kreatech Genicon Luminex Zeptosens Affymetrix Proteomics Polysciences Genicon Luminex 5 Cellomics Polysciences

6 Revenue breakdown of product launches in 2002 Approx. 70% of revenues coming from new introduced products will be within QIAGEN s core business Related Products: DNA/RNA purification, separation, and handling Zeptosens SensiChip Microarray Reader Luminex LiquiChip Suspension Array System Polysciences BioMagnetic Cell Separation 6

7 QIAGEN Fourth Quarter 2001 Q Q Growth Revenues ($ million) % currency adjusted % EBIT margin (%) % Operating Income ($ million) % Net Income ($ million) % EPS $ 0.08 $ % WA Number of Shares Products (approx.) % 7

8 QIAGEN Full Year Growth Revenues ($ million) % currency adjusted % Operating Income ($ million) % adjusted 55.3* 41.9* 32% Net Income ($ million) % adjusted 36.2* 26.4* 37% EPS $ 0.24 / 0.25* $ 0.14 / 0.18* 39% WA Number of Shares Employees (approx.) 1,557 1,309 19% Cash, Marketable Securities ($ million) (* figures excluding one-time charges related to the acquisitions of Operon Technologies Inc and Sawady Group without considering any other impacts related to these acquisitions)

9 QIAGEN s Product Breakdown 2001 Synthetic DNA Consumables Others Instruments 3% 13% 13% 71% 9

10 QIAGEN Underlying Growth US$ million Consumables +27% Others Synthetic DNA Instruments Consumables Q Q4 2001

11 Expanding EBIT margin QTD % COGS R&D S&M G&A EBIT US$ million % 9% 27.5% 12.5% 19% 10% 24% 11% 24% 11 Q Q4 2001

12 2002 is a pretty normal year in terms of cumulative new product introductions pro forma excluding Q3/Q4 disruptions 2002 "as if" evenly launch of new products ~ 28% ~ 28% ~ 28% 70 ~ 28% 60 Q1 Q2 Q3 Q4 12

13 13 Highlights 2001 Integration of QIAGEN Operon Inc. (formerly Operon Technologies Inc.), acquired in June 2000 and commenced manufacturing activities at a new European Operon facility in Cologne, Germany Strategic alliance on ultra-high throughput sample and liquid handling automation with Zymark Corporation Launch of the first product of our PreAnalytiX joint venture with Becton Dickinson (NYSE: BDX): the PAXgene Blood RNA system Acquisition of Sawady Group of companies in Tokyo, Japan, a leading company supplying DNA products to the emerging Japanese Life Science markets DNA microarray technology agreements with Aventis and Bayer covering the Sensichip Workstation Strategic alliance on ultra-sensitive microarray labeling and detection technology with Genicon Sciences Agreement for multi-application labeling technology with Kreatech Biotechnology B.V. Strategic alliance on magnetic polymer bead technologies with Polysciences Inc. Alliance to develop and market next generation nucleic acid separation and purification products with Pall Corporation

14 Employees December 31, 2001 USA Ger UK F CH Aus JP NL Italy Total % Production % R&D % Sales % Marketing % Admin % Total % 14

15 QIAGEN Financial Calendar 2002 May 06, 2002 Q June 14, 2002 Annual General Meeting, Venlo August 05, 2002 Q2, First Half 2002 October 28, 2002 Q

16 Highlights 2002 Opening of the production facility in Germantown, Maryland January 2002 Launch BioMag Magnetic Cell Separation (Cells/DNA) Q Launch Rneasy 96 for BioRobot 8000 Q1/Q Launch SensiChip Microarray Reader System Q Opening of the new buildings in Hilden, Germany July 2002 Launch Clinical BioRobot Generation Q Launch Luminex LiquiChip Suspension Array System Q

17